
MPLT Stock Forecast & Price Target
MPLT Analyst Ratings
Bulls say
MapLight Therapeutics is attractive because its ML-007C-MA program targets two large, underserved CNS markets—schizophrenia and Alzheimer’s disease psychosis—with a differentiated muscarinic mechanism designed to improve efficacy while reducing peripheral side effects and simplifying dosing. The company’s schizophrenia data showed a 210mg/3mg BID dose with a 4.5-point placebo-adjusted PANSS improvement, a 0.37 effect size, cognitive benefit, and only 7.1% discontinuations from TEAEs, suggesting a credible safety/tolerability profile versus competing therapies. Upstream, the ongoing VISTA trial in ADP and the potential for positive ADEPT readouts could validate the mechanism, while the reported $150M PIPE financing supports execution and lowers near-term funding risk.
Bears say
MapLight Therapeutics is viewed negatively because ML-007C-MA failed to hit the primary endpoint, while psychiatrists described its food-flexibility benefit as insufficient to offset weaker efficacy versus Cobenfy and questioned the adequacy of 5-week data for a chronic psychiatric disorder. The muscarinic market has shifted from an open field to a contested one, with Cobenfy setting the efficacy benchmark and compressing MapLight’s differentiation, while schizophrenia safety concerns and loss of tolerability advantage further limit adoption potential. As a result, the company faces lower modeled peak sales of about $400mn/$2bn in schizophrenia/ADP in 2037E, more judicious operating expenses, and a higher likelihood of additional financing needs.
This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MPLT Analyst Forecast & Price Prediction
Start investing in MPLT
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About MapLight Therapeutics Inc (MPLT) Forecast
MPLT Analyst Forecast & Price Prediction
Start investing in MPLT
Order type
Buy in
Order amount
Est. shares
0 shares